In combination with reperfusion therapies after stroke, many previously developed immune-related drugs, including the toll-like receptor 4 (TLR4) antagonist ApTOLL,11 methylprednisolone,13 edaravone dexborneol,12 fingolimod (FTY-720),14 and bone marrow mononuclear cell transplantation,60 have yielded promising results. Here, TLR4 is linked to stroke disorder.